Comparing pain relief methods after breast surgery: a study on new and traditional approaches

Submission date	Recruitment status	Prospectively registered
12/10/2024	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
15/10/2024	Completed	Results
Last Edited	Condition category	Individual participant data
15/10/2024	Surgery	[X] Record updated in last year

Plain English summary of protocol

Background and study aims

There is currently inconclusive evidence on whether liposomal bupivacaine plus bupivacaine hydrochloride (LB-BH) confers better post-lumpectomy analgesia than standard bupivacaine hydrochloride (BH). This study aimed to compare patient-reported pain control and clinical outcomes.

Who can participate?

Any patients who are able to consent over age 18 who undergoing only lumpectomies of their breast for any reasons.

What does the study involve?

Receiving LB-BH injection prior to the incision or BH alone and watch for pain management on that side

What are the possible benefits and risks of participating? Same benefit of analgesia but 20-30 times less money and no narcotics sent home with, so helping with opioid epidemics

Where is the study run from? University of Michigan Health-Sparrow (USA)

When is the study starting and how long is it expected to run for? February 2023 to February 2024

Who is funding the study? Investigator initiated and funded

Who is the main contact? Irada Mamukadze, irada.mamukadze@umhsparrow.org

Contact information

Type(s)

Scientific, Principal Investigator

Contact name

Dr Thais Fortes

Contact details

1215 E. Michigan ave Lansing United States of America 48912 +1 9372191095 thais.fortes@umhsparrow.org

Type(s)

Public, Scientific

Contact name

Dr Irada Mamukadze

ORCID ID

http://orcid.org/0009-0005-0865-0926

Contact details

935 Whittier Dr East Lansing United States of America 48823 +1 9372191095 Irada.Mamukadze@umhsparrow.org

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

1967230-3

Study information

Scientific Title

Comparing post-lumpectomy analgesia using enhanced recovery after surgery (ERAS) protocol with and without liposomal bupivacaine: randomized controlled trial

Acronym

ERAS

Study objectives

Liposomal Bupivacaine and Bupivacaine hydrochloride have same efficacy on pain control

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 15/02/2024, Sparrow Health System IRB (1215 Michigan Avenue, Lansing, MI, 48912, United States of America; +1 5173645016; irb@sparrow.org), ref: 2228

Study design

Single-center patient-blinded prospective randomized controlled trial who undergo lumpectomy

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Efficacy

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Use of bupivacaine hydrochloride during lumpectomy surgery

Interventions

Patients were randomized in a 1:1 ratio to either the intervention group Bupivacaine Liposomal with Bupivacaine Hydrochloride (LB-BH) or Bupivacaine Hydrochloride alone (BH) using a clinical trial randomization tool from the National Cancer Institute. Randomization was stratified based on the recruitment site and type of surgery (lumpectomies with and without SLNB). The treatment groups were balanced using randomly assigned numbers. The injection of LB-BH or BH were given prior to incision. Then on day 2 of post surgery a nurse called to ask for pain level 0-10 with 0 being no pain at all and 10 being the worst pain they ever had, then same question was asked on post surgery day 9. Then, they were chart checked from electronic medical record to see if they called offices for pain related questions or asking for opioid pain medications or had ED visits.

Intervention Type

Drug

Pharmaceutical study type(s)

Bioequivalence

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Bupivacaine hydrochloride and bupivacaine hydrochloride

Primary outcome measure

Pain measured using NRS on day 2 and day 9 post surgery

Secondary outcome measures

Adjunctive opioid use, pain-related ED visits, office calls, requests for pain scripts measured using patient records after day 9 post surgery

Overall study start date

15/02/2023

Completion date

28/02/2024

Eligibility

Key inclusion criteria

Adults over the age of 18 who undergo lumpectomies and able to consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

99 Years

Sex

Both

Target number of participants

200

Total final enrolment

76

Key exclusion criteria

- 1. Patients undergoing any other procedures other than lumpectomies
- 2. Patients who are getting lumpectomies with any other procedures

Date of first enrolment

21/04/2023

Date of final enrolment

23/02/2024

Locations

Countries of recruitment

United States of America

Study participating centre University of Michigan health-Sparrow

1200 E Michigan ave Lansing United States of America 48912

Sponsor information

Organisation

University Of Michigan-Sparrow Health

Sponsor details

1200 E. Michigan ave Lansing United States of America 48912 +1-517-364-5402 irb@umhsparrow.org

Sponsor type

Research organisation

Website

https://www.uofmhealthsparrow.org/

Funder(s)

Funder type

Funder Name

Not Consumed

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United States of America

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal

Intention to publish date

15/10/2024

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request irada.mamukadze@umhsparrow.org

IPD sharing plan summary

Available on request